MLYS biotech catalysts & pipeline

MINERALYS THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

lorundrostat — PDUFA

Dec 22

Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

Source filing

Mineralys Therapeutics — Conference presentation

Nov 6–Nov 9

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Source filing

Explore the free biotech catalyst calendar